Fennec Pharmaceuticals (FENC) vs Galectin Therapeutics (GALT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Fennec Pharmaceuticals (FENC) has outperformed Galectin Therapeutics (GALT) over the past year, gaining 9.3% versus a loss of 24.1%. Over five years, FENC leads with a +12.7% price change compared with +7.4% for GALT. Fennec Pharmaceuticals is the larger company by market cap ($372.8 million vs $367.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FENC | GALT |
|---|---|---|
| Share price | $10.63 | $3.64 |
| Market cap | $372.76M | $367.09M |
| 1-day change | +2.61% | +0.55% |
| YTD return | +34.55% | -12.98% |
| 1-year return | +9.28% | -24.11% |
| 5-year return | +12.73% | +7.42% |
| Forward P/E | 11.21 | — |
| EPS (TTM) | $-0.12 | $-0.43 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $13.25 | $7.13 |
| 52-week low | $5.65 | $2.03 |
| Distance from 52-week high | -19.77% | -48.95% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +66.23% | +202.20% |
| Average volume | 193.31K | 385.71K |
| Shares outstanding | 35.07M | 100.85M |
| Employees | 35 | 9 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- FENC has outperformed GALT by 33.4 percentage points over the past year.
About Fennec Pharmaceuticals
FENC stock →Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 35 employees
About Galectin Therapeutics
GALT stock →Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hypertension.
Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees
FENC vs GALT FAQ
Which is bigger, Fennec Pharmaceuticals or Galectin Therapeutics?
Fennec Pharmaceuticals (FENC) is larger, with a market capitalization of $372.76M compared with $367.09M for Galectin Therapeutics (GALT).
Which stock has performed better over the past year, FENC or GALT?
FENC returned +9.28% over the past 12 months, compared with -24.11% for GALT (price return, excluding dividends). Past performance does not predict future results.
Are Fennec Pharmaceuticals and Galectin Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Fennec Pharmaceuticals and Biotechnology: Pharmaceutical Preparations for Galectin Therapeutics.